Compare MIR & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIR | STVN |
|---|---|---|
| Founded | 2005 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Containers/Packaging |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.4B |
| IPO Year | N/A | 2021 |
| Metric | MIR | STVN |
|---|---|---|
| Price | $22.31 | $16.03 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 2 |
| Target Price | ★ $28.38 | $23.75 |
| AVG Volume (30 Days) | ★ 3.2M | 1.0M |
| Earning Date | 02-10-2026 | 03-05-2026 |
| Dividend Yield | N/A | ★ 0.41% |
| EPS Growth | N/A | ★ 19.61 |
| EPS | 0.11 | ★ 0.60 |
| Revenue | $925,400,000.00 | ★ $1,373,219,524.00 |
| Revenue This Year | $24.27 | $8.42 |
| Revenue Next Year | $7.48 | $9.61 |
| P/E Ratio | $204.64 | ★ $26.78 |
| Revenue Growth | ★ 7.50 | 6.97 |
| 52 Week Low | $12.00 | $13.91 |
| 52 Week High | $30.28 | $28.00 |
| Indicator | MIR | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 32.13 | 39.17 |
| Support Level | $20.84 | $15.06 |
| Resistance Level | $24.30 | $16.69 |
| Average True Range (ATR) | 1.15 | 1.03 |
| MACD | -0.46 | 0.13 |
| Stochastic Oscillator | 11.80 | 43.54 |
Mirion Technologies Inc provides products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience. The Company manages its operations through two segments: Nuclear & Safety and Medical. The Medical segment improves the quality and safety of cancer care delivery and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment powers advancements in nuclear energy and critical radiation safety, measurement and analysis applications across laboratories, research and other industrial markets such as defense.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.